Expression and Clinical Significance of Novel Long Noncoding RNA Fibroblast Growth Factor 10AS and FGF10 in Colorectal Cancer.

OBJECTIVE

Colorectal cancer (CRC) imposes great health burdens worldwide. Growth factors contribute to cell growth, differentiation, angiogenesis and, most importantly, tumour formation in many types of cancers. Natural antisense transcripts (NATs) are inclusively predicted to play a major role in cancer progression. The present study aims to evaluate the relationship of fibroblast growth factor 10 () and novel long noncoding RNA (lncRNA) antisense () expression with clinicopathologic features in CRC progression to designate a biomarker for CRC early detection.

MATERIALS AND METHODS

This cross-sectional study was conducted on 100 CRC tumour and parallel adjacent normal tissues. We added 30 normal cases to enhance accuracy of the test. The expression levels of and were evaluated by real-time polymerase chain reaction (PCR). The findings were validated by measuring expression levels in the HT29 and SW480 cell lines. Immunohistochemistry analysis was performed systematically to evaluate FGF10 protein expression. The Mann-Whitney U test with Cox regression analysis were applied. P<0.05 were designated as significant.

RESULTS

A significant increase in expression was observed in (P<0.001) along with a significant decrease in (P<0.02) in the tumour tissues in comparison with the adjacent normal tissues. Upregulation of and downregulation of expression were strongly correlated with the Tumour, Node, Metastasis (TNM) stage (P<0.007 and P<0.004), vascular invasion (P<0.03 and P<0.01), lymph invasion (P<0.02 and P<0.04), and differentiation (P<0.01 and P<0.02), respectively. Moreover, the area under the receiver operating characteristic (ROC) curve for the prognostic value of was about 0.84 (95% confidence interval [CI]: 0.771-0.912). Linear regression analysis confirmed a negative correlation between expression and its antisense transcript (r=-0.02).

CONCLUSION

The relationship between the expression levels of and in tumour tissues and adjacent normal tissues indicated that sense and antisense RNAs could be remarkable prognostic biomarkers for achieving effective and primitive treatment.